Introduction Macroautophagy is an important contributor of cellular homeostasis, and therefore is active and up regulated in various conditions of cellular stress and inflammation. The pathway has been implicated in shaping the innate and adaptive immune responses by acting at multiple and diverse levels including cytokine secretion and antigen presentation. Objectives Our aim is to analyse the contribution of macroautophagy in antigen presenting cells to the adaptive immune response in the context of arthritis. We analysed the antigen induced arthritis model in mice that are deficient in autophagy in their dendritic cells. Methods CD11c-Cre mice (C57BL/6), (Jackson Laboratory) were crossed with Atg5 flox/flox mice (C57BL/6) provided by Dr. Noboru Mizushima (Japan). ATG5 is an essential autophagy gene, its targeted deletion in dendritic cells completely abolished a functional autophagy pathway in these cells (DC/ ATG5 -/-).For the antigen induced arthritis mice model (AIA), mice were immunised with methylated BSA (mBSA) and CFA. Monoarthritis was induced at day 21 by injection of mBSA into the knee joint and animals sacrificed at day 28. Sections from knees were stained with hematoxylin and eosin for macroscopic scoring of the cellular infiltrate. In parallel, toluidine blue staining was used for cartilage damage. T cell function was monitored by cytokine production by ELISA, after in vitro re-stimulation with mBSA or CD3/CD28 for 72 hour, using single cell suspensions from lymph nodes. Results Mice lacking autophagy in their dendritic cells (DC/ ATG5 -/-) showed enhanced cartilage destruction and bone erosion. Interestingly, the Th1/Th17 response in DC/ATG5 -/-mice was significantly increased. In parallel this phenotype was linked to a decreased Foxp3 expression in the regulatory T cell (Treg) population. Introduction Rheumatoid arthritis (RA) develops upon aberrant activation of the immune system mainly due to failure of self-tolerance mechanisms. 1 Abatacept, approved for RA treatment, a recombinant fusion protein of the extracellular domain of human cytotoxic T lymphocyte antigen 4 (CTLA4), restricts T cell activation by blocking interaction of CD80/ CD86 on dendritic cells (DCs) to CD28 on T cells. 2 In clinical practice, approximately 40-50% of RA patients treated with abatacept, respond to therapy in the first 6 months. 3 Development of a predictor of response is of clinical and immunological significance. Objectives Herein, we sought to investigate for early biomarkers of response to abatacept, based on a detailed immunological profile of peripheral blood cells and cytokines. Methods RA patients (ACR/EULAR 2010 criteria) who started abatacept due to highly active disease, were recruited to perform immunological studies at baseline, 3 and 6 months of therapy. Peripheral blood mononuclear cells (PBMCs) were isolated and pathogenic IL-17 and IFN-g producing CD4+ T cells (Th1, Th17), regulatory (Tregs) T cell subsets as well as myeloid cell populations, like DCs and myeloid derived suppressor cells (MDSCs) were characterized using flow cytometry. Response to therapy (remission or low disease activity) was assessed based on the "Swollen joints" value. Results We studied 21 patients (mean age 60 years, 86% women, 48% rheumatoid factor or anti-citrullinated protein antibody positive). After 6 months of treatment, 45% of them attained remission or low disease activity. Notably, baseline levels of Th17 were statistically significant decreased in peripheral blood of patients in remission or low disease activity compared to those with active disease at 6 months of treatment ( Conclusions In this cohort of RA patients treated with abatacept (CTLA4Ig), low levels of IL-17 producing CD4 + T cells at baseline are associated with a better response to abatacept at 6 months. This novel finding (validation to a larger cohort in progress) may be used as an early biomarker to predict clinical responses to abatacept.
